RecruitingNot ApplicableNCT07238699
An Evaluation of the Safety and Tolerability of Ocular Lubricants
Sponsor
Alcon Research
Enrollment
148 participants
Start Date
Mar 4, 2026
Study Type
INTERVENTIONAL
Conditions
Summary
The purpose of this study is to evaluate the safety and tolerability of two new artificial tear formulations in subjects with moderate dry eye disease.
Eligibility
Min Age: 18 Years
Inclusion Criteria4
- Subject must be willing and able to understand and sign an ethics committee approved informed consent form.
- Subject must be willing and able to attend all study visits as required by the protocol.
- Subject must exhibit symptoms of dry eye at the Screening Visit.
- Subject must currently use artificial tears.
Exclusion Criteria4
- Has any known active ocular disease and/or infection.
- Has any known infection or inflammation that requires treatment or has a systemic condition that, in the opinion of the investigator, may affect a study outcome variable.
- Any ocular injury to either eye in the 12 weeks prior to screening.
- Current wearer of contact lenses or has a history of contact lens wear within the previous 1 month.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
OTHERFID123440 test formulation
Investigational product
OTHERFID123437 test formulation
Investigational product
OTHERFID123440 test formulation
Investigational product
Locations(4)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07238699
Related Trials
A Study Evaluating the Safety and Efficacy of a Fixed-Dose Combination for Dry Eye Disease
NCT0712862832 locations
A Clinical Study to Evaluate the Effect and Side Effect of a New Artificial Tear Formulation (ABBV-444) Compared to Refresh Optive Unit Dose in Adult Participants With Dry Eye Disease
NCT0728438120 locations
Evaluating the Safety, Tolerability, and Efficacy of GRF312 5% in Participants With Dry Eye Disease (DED).
NCT0726451710 locations
A Study on the Correlation Between Tear Iron Levels and the Severity of Dry Eye Disease.
NCT073638241 location
Efficacy and Safety of BUFY01 Versus SVS20 in the Treatment of Dry Eye Disease
NCT058653792 locations